MN HF3217

Limits cost-sharing for enrollees prescribed FDA-approved biologic products whose gross income is at or below 400 percent of federal poverty guidelines to not exceed the lowest-cost nonconformary brand-name medication in their health plan's formulary.

Caps cost-sharing for enrollees prescribed FDA-approved biologic products whose gross income exceeds 400 percent of federal poverty guidelines at double the lowest-cost nonconformary brand-name medication cost-sharing in their health plan's formulary.

Defines "biologic product" to include viruses, therapeutic serums, toxins, antitoxins, vaccines, blood, blood components, allergenic products, protein-based peptide products, arshenamine derivatives, and other trivalent organic arsenic compounds applicable to disease prevention, treatment, or cure.

Applies to coverage issued or renewed on or after August 1, 2010.